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Introduction: Nowadays, versatile and useful features of nanoparticles, 
especially gold nanoparticles in medicine and healthcare have brought them 
immense popularity. The ability to transfer towards the 
special cells, distinguish the different cells and their electrical resonance 
feature make them as a proper candidate for treatment of cancer. Antibodies 
which are generated against death receptor, DR5, are powerful tools in 
the programmed death of cancer cells during induction process. Its association 
with nanoparticles could efficiently deliver such biological apoptosis inducing 
drug to the cancer cells 
Materials and Methods: In this study, at the first step, gold nanoparticles were 
produced by chemical methods in the presence of aspartic acid (amino 
acid). Then, nano-sized ones were selected and subsequently 
conjugated by mouse antibodies which were produced against a small 
21 amino acid peptide from extracellular domain of death receptor, DR5.  
Results: The conjugated antibodies by gold nanoparticles could efficiently kill 
the MCF7 breast cancer cells through inducing cell death. The combination 
of antibodies which were generated against a small fragment of the death 
receptor,  
Conclusion:DR, with gold nanoparticles not only minimized the 
required amount for the purpose of inducing cell death.but 
also maximizing their efficiency and quality.  
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     The developments of nontoxic and 
biocompatible magnetic particles have been 
clarified for biological applications since 
mid-1980s [1]. Magnetic particles have 
great features as high performance 
biomaterial used for transport and 
separation of cells [2], MRI [3], 
hyperthermia [4] and drug delivery [5]. 
Nowadays, nanocarriers encounter 
numerous barrier enrooted to their target, 
such as mucosal barriers and non-specific 
uptake [6,7].  
Tumors have some general features like 
leaky blood vessels and poor lymphatic 
drainage. Free drugs may diffuse 
nonspecifically and nanocarriers can 
extravasate into the tumor tissue via leaky 
vessels by EPR (enhances permeability and 
retention) effect [8,9]. Experiments 
performed through using liposomes of 
different mean size suggest that the 
threshold vesicle size for escape into tumor 
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is ~400 nm [11] while other studies have 
shown that particles with 200 nm diameters 
are more effective [6, 10, 11]. Nowadays, 
developments in the field of antibody-
conjugated NPs have demonstrated 
attractive results in both in vitro and in vivo 
conditions. Even more advanced 
pharmacotherapy agents can exhibit a very 
low accumulation into the disease site, and 
an extensive biodistribution into healthy 
tissues. As a consequence, long-term 
pharmacotherapy is characterized by 
significant inefficacy and severe toxicity. 
Tumor necrosis factor-related apoptosis- 
inducing ligand, TRAIL, particularly 
triggered apoptosis upon engagement by 
one of its two agonist receptors, DR4 [12] 
and DR5 [13]. The ligands displays specific 
antitumor activity against a wide range of 
tumor cells [14,15] without significant side 
effects [16]. This extrinsic apoptotic 
pathway has been targeted by two 
approaches: recombinant human TRAIL 
ligands [17,18] or its agonistic antibodies 
against DR4 and DR5 [19-21]. In contrast, 
antibodies are cheaper and more acceptable 
in direct contrast to ligands. In this research, 
the cell death  inducing antibodies were 
conjugated to gold nanoparticles and used 
as a potential weapon against MCF7 cancer 
cells. 
 
2. Materials and Methods 
2.1 Peptide Synthesis 
     A little epitopes from extracellular 
domain of human DR5 protein with 21 
amino acids was produced by peptide 
synthesizer and after confirmation via GC 




     Six-week-old BALB/c female mice were 
immunized by intradermal route, using  
purified synthetic peptide (350μg). Briefly, 
mice were immunized in two groups: the 
first group with peptide and complete 
Fround`s (Razee institute, Iran) adjuvant 
and the second group received the 
KLHadjuvant.  
There were two different kinds of control 
groups, non-immunized mice and 
immunized with pure adjuvants. The 
immunization was completed by injecting 
three times boosters with 2 weeks interval 
of incomplete Freund`s and KLH adjuvant 
(with an equal volume of peptides). Thirty-
five days later, the sera were collected for 
determining the IgG titers of antibody by 




     The ELISA assay was completed in 
ELISA strips. The procedure was started by 
coating 20µg (per 100µl coating buffer) of 
recombinant whole DR5 protein (which 
were produced in our laboratory, under 
publish); then, they were incubated an over-
night in 4
o
C. The blocking took 60 min 
incubation with fat-milk. Then, the IgGs 
were added (dilutions 1:1000 to 1:64000) 
and incubated for 30 min at 37
0
C. It was 
followed by incubation with secondary 
antibodies (goat derived anti-hen-IgG). 
HRP was conjugated under the same 
condition. Washing occurred in every step 
with PBST for 3 times. At the last step, 
absorbance of TMB reaction result with 
HRP was measured at either 450 nm 
(reactions stopped with 1M hydrochloric 
acid). 
 
2.4 Nanoparticle Synthesis 
     1.5 ml of 25 mM aspartic acid solution 
was added to 2.5 ml of de-ionized water and 
the mixture was heated till boiling. Upon 
boiling, 5ml of chloroauric acid solution 
(such that the molar ratio of aspartic acid to 
chloroauric acid was adjusted to 7.5) was 
added to this mixture under vigorous 
stirring and heating conditions till boiling. 
After a few minutes, the reduction of the 
gold salt (Au
3+
) to GNPs (Au
0
) was 
confirmed by the appearance of a dark-red 
colloidal solution. When the color of the 
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colloid stabilized, the reaction was rapidly 
quenched in ice [22]. 
 
2.5 Conjugation  
     By means of electrostatic and 
hydrophobic binding interactions between 
GNPs and antibodies, conjugation took 
place. For preparation of GNPs–antibody 
conjugates, GNPs (600 μg) were mixed 
with the antibody solution (300 μg). To 
complete the process, the mixture was 
stirred overnight at room temperature. 
 
2.6 UV–Vis Spectrophotometery 
     The optical properties of the gold 
colloidal solution (with and without 
conjugation) were monitored on a Shimadzu 
dual beam spectrophotometer (Model 1601) 
in the range of 300–700 nm. Quartz 
cuvettes with 1 cm optical length were used 
for all measurements. 
 
2.7 Cell Culture 
     The MCF7 cell lines (human breast 
cancer) were grown in RPMI 1640 medium 
with 10% fetal calf serum (V/V) and 1% 
penicillin/streptomycin. Cells were 
incubated at 37
o
C with 5% Co2. 
 
2.8 MTT Assay 
     The process began by incubation of 10
4
 
cells per well in 96-well for 24 hours in 
37
0
C and 5% Co2. In the other day, the 
medium was removed and the cells were 
incubated with 100 ml of MTT solution for 
2 hours in mentioned conditions in a dark 
incubator. The supernatant ease was 
removed and the produced color was 
resolved in 200 ml acidic isopropanol and 
was mixed properly. The absorbance of the 





     The small peptides as an antigen 
essentially need a strong kind of adjuvant to 
properly induce the immune system of 
animals. The immunization of mice in this 
project was executed through two different 
kinds of adjuvants (first with common 
adjuvant, Fround`s adjuvant (21A), and 
second a specific adjuvant for small 
peptides, KLH one (21K)). The blood 
sample was collected, with the  ELISA 
results significantly demonstrating the 
antibody production in mice. Antibodies 
specifically reacted to the DR5 whole 
protein which was produced in our 
laboratory (under publish) (figure 1).  It 
seems that both of adjuvants could induce 
the immune system properly, though as 
expected, those mice which were 
immunized by antigen and KLH adjuvant 
remarkably displayed better results and 
obtained antibodies were more significant. 
In contrast to test group antibodies, the 
control group’s antibodies (by receiving just 
Fround`s adjuvant (control-A), just KLH 
adjuvant (control-K)) and the antibodies 
from non-immunized mice (control) had no 
affinity to the target protein (DR5). 
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Figure 1. ElISA result of produced IgY against extracellular domain of DR5 ( 21amino acids).ElISA of mice antibody 
immunized which by antigen and Fround`s adjuvant (21A), with antigen and KLH adjuvant (21K), the golf nanoparticle 
conjugated of them (21AN and 21KN, sequentially), with just Fround`s adjuvant (control-A) and without injection 
(control). Numbers in y axis is dilution sequentially (1/1000, 1/2000, 1/4000, 1/8000, 1/16000, 1/32000 and 1/64000). P 
value of 21, is 0.00041 that are according to p<0.05, have sense. 
 
3.2 Nanoparticle Production and 
Conjugation 
     At the first step, HAuCl4 salt was 
reduced by adding the aspartic acid to 
produce the nanogold-particles. The 
carboxyl group of aspartic acid interacts 
with the desired antibody and allows it to 
make antibody-nanoparticle complex. 
Figure 2 shows the UV-Vis spectrum of 
colloidal gold nanoparticle. As seen in 
figure 2, the gold nanoparticle and the 
conjugated antibody shows a brand 
absorption in 530 nm. The shift in top hill 
of the conjugated antibody confirmed the 




Figure 2. UV-visible spectrum. Colloidal gold nanoparticles (up, green). UV–Vis spectra of antibody-nanoparticle 
complex (down, blue). 
 
 
3.3 Anticancer Analysis 
     Cell death-inducing activity of two kinds 
of IGGs, gold nanoparticle conjugated 
(21AN, produced antibody against the 
peptide injected by Fround`s adjuvant 
conjugated with gold nanoparticle and 
21KN, antibody from immunized hens by 
antigen and KLH adjuvant conjugated with 
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gold nanoparticle) and without any 
manipulations (21A and 21K) were 
evaluated on MCF7 breast cancer cells. The 
cells were treated with various 
concentrations of obtained antibodies; then, 
0.25 µg/ml were chosen and allowed to act 
on cells for 24 hours. The cell viability in 
the last point was determined by MTT 
assay. It was not surprising that they could 
specially kill the cancerous cells, though the 
better activity of conjugated antibodies was 
significant (figure 3). The reduction of 
acquired concentration of antibody in these 
concentrations had no death effect; hence, 
they were omitted in figure 3. The 
significant differences between two kinds of 
antibodies emphasize their conjugation 
efficiency with gold nanoparticle. 
Additionally, among two conjugated IgGs 
(21AN and 21KN), the second one, as 
expected, had the best effect on induction 
death. 
 
Figure 3. MTT results. (A) Toxicity percentage of IgGs (21A,21K and 21AN, 21KN) on MCF7 cells. The P value is 
0.000042 according to P<0.05 has no sense.The percentage of toxicity was calculated BY using the following formula: 




     In cancer therapy world, researchers are 
trying to find special agents which could 
acceptably deliver to the target cells. DR4 
and DR5 share significant similarity in the 
structure of their genes, expression 
pathways in human body and signaling 
downstream The mature DR5 receptor 
contains 411 amino acids, including three 
cysteine-rich repeats in external domain [ 
23]. DR4 and DR5 showed high identity 
which was about 66% [12,24-26], but for 
the present research, DR5 has been 
chosen.DR5 was described as contributing 
more than DR4 to the overall apoptotic 
activity of TRAIL in apoptosis signaling 
cancer cells [27-29]. The results confirmed 
such predictions. Hemocyanins act as 
oxygen-transporting proteins in many 
arthropod and mollusc species [30]. In 
addition to this biochemical function, the 
hemocyanin of the Californian giant 
keyhole limpet Megathuracrenulata, 
amarine gastropod, is known to be a potent 
immune activator [31, 32]. Small peptides 
special adjuvant, KLH, significantly worked 
better and strongly recommended 
THATUSE in such immunization. Gold 
nanoparticles (NPs) could be used for basic 
diagnostic strategies [33] and therapeutic 
purposes [34], which are both based on 
physical characterization of gold NPs. 
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Furthermore, such particles have extra 
benefits: they are resistant to oxidative 
corrosion and are therefore considered 
stable to the various environments 
encountered within the human body. Gold 
would appear safe in in-vivo, though 
beyond this fact they have demonstrated a 
significant reduction in cell viability when 
exposed to high concentrations of gold-
based NPs [35]. The amino acids in 
nanoparticle production challenged its N-
terminal with Au and the other free C-
terminal group could interact with several 
kinds of proteins such as antibodies. 
Attachement of functionalized gold 
nanoparticles to antibodies makes a stable 
nanoparticle complex. Special attention is 
given to recent advances in these 
engineering approaches: specifically, to 
target nano-medicines against severe 
diseases and to the development of 
multifunctional nano-platforms for 
combined selective diagnosis and effective 
pharmacotherapy.   
The cell-specific endocytosis of the NP at 
the site of disease provides an attractive 
feature for a variety of diagnostic and 
therapeutic strategies. Furthermore, an 
additional feature of such kind of NPs 
mediated delivery is the possibility of 
inducing multivalent receptor activation to 
trigger receptor-activated signaling, leading 
to downstream effects of such apoptotic 
signaling [36]. In addition, some of these 
studies have shown that NP size and surface 
 ligand density are referred to as critical key 
features [37]. According to MTT results, 
our produced antibodies significantly kill 
the MCF7 cancer cells. And yet, in contrast 
to the normal antibodies, the conjugated 
ones with gold nanoparticle, having huge 
differences in the same concentration, have 
the ability to kill the cells. Additionally, the 
results confirmed our latest experiences of 
antibodies against 21 aminoacids [38]. This 
newly produced antibody (by administering 
the two new adjuvants instead of liposomes) 
could also recognize the DR5 protein 
properly and the results proved to be more 
acceptable. Several researchers introduced 
different kinds of monoclonal antibodies 
against DR5 protein [39-43] which are 
expensive and difficult to obtain. They also 
poorly induce death in cancer cells and 
mainly need manipulations in their structure 
or extra components such as chemotherapy 
agents to be effective. Immunizing the mice 
against 21 aminoacid length peptide 
extracted from the extracellular domain of 
DR5 protein by injecting with KLH 
adjuvant in contrast to other kinds of 
adjuvants (Freund or liposomal constructs) 
were remarkably more efficient. 
Significantly, their conjugation to gold 
nanoparticles reduces the minimum 
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